medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2017, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2017; 64 (1)

Prevalence of antinuclear antibodies in apparently healthy individuals. Lima, Peru

La Rosa FCB, Lozano FVS

Language: Spanish
References: 40
Page: 8-13
PDF size: 244.91 Kb.


ABSTRACT

Introduction: Antinuclear antibodies are serologically markers of autoimmunity, however this test is currently facing major challenges, and it seems the most important is the presence of these antibodies in healthy people. Objective: To determine the prevalence, pattern and titer of antinuclear antibodies in apparently healthy subjects. Material and methods: A prospective, analytical, cross-sectional study was performed on 150 blood donors for the determination of antinuclear antibodies using the indirect immunofluorescence technique in HEp-2 cells. Results: The prevalence of antinuclear antibodies was 10.7% (95% CI 5.8-15.6%). The frequency increased with age and was higher in females than in males (12.3% versus 9%, p ‹ 0.001), prevalent patterns were 31.3% fine mottling and 25% dense fine mottling, and the most frequent titers were 1:80 (68.8%) and 1:160 (12.5%). The dense fine speckled pattern was found in low, medium and high titers. Conclusions: The prevalence found was comparable to what was reported in other countries, it was higher in women and older persons. The titer is a relative value parameter, whereas the fluorescence pattern may have a more decisive impact.


REFERENCES

  1. Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev. 2015; 14 (6): 555-563.

  2. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989; 44: 93-151.

  3. Satoh M, Chan EK, Sobel ES, Kimpel DL, Yamasaki Y, Narain S et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol. 2007; 3 (5): 721-738.

  4. Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol. 2009; 15 (7): 325-329.

  5. Cabiedes J, Núñez-Álvarez C. Antinuclear antibodies. Reumatol Clin. 2010; 6 (4): 224-230.

  6. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010; 69 (8): 1420-1422.

  7. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014; 73 (1): 17-23.

  8. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011; 63 (1): 191-200.

  9. Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren’s syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol. 1985; 36 (1): 120-128.

  10. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004; 50 (3): 892-900.

  11. Rosenberg AM, Semchuk KM, McDuffie HH, Ledingham DL, Cordeiro DM, Cessna AJ et al. Prevalence of antinuclear antibodies in a rural population. J Toxicol Environ Health A. 1999; 57 (4): 225-236.

  12. Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S et al. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol. 2008; 18 (2): 153-160.

  13. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011; 13 (2): R38.

  14. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349 (16): 1526-1533.

  15. Pisetsky DS. Antinuclear antibodies in healthy people: the tip of autoimmunity’s iceberg? Arthritis Res Ther. 2011; 13 (2): 109.

  16. Wang KY, Yang YH, Chuang YH, Chan PJ, Yu HH, Lee JH et al. The initial manifestations and final diagnosis of patients with high and low titers of antinuclear antibodies after 6 months of follow-up. J Microbiol Immunol Infect. 2011; 44 (3): 222-228.

  17. Fernandez-Solange AV, Lobo-Alice ZC, Oliveira-Zilda NP, Fukumori-Ligia MI, Périgo AM, Rivitti EA. Prevalence of antinuclear autoantibodies in the serum of normal blood dornors. Rev Hosp Clin. 2003; 58 (6): 315-319.

  18. Hilário MO, Len CA, Roja SC, Terreri MT, Almeida G, Andrade LE. Frequency of antinuclear antibodies in healthy children and adolescents. Clin Pediatr (Phila). 2004; 43 (7): 637-642.19.

  19. Uibo R, Talja I, Jôgi R, Janson C, Björnsson E, Boman G et al. Autoantibodies in Estonia and Sweden, populations with different responses to allergens. Int Arch Allergy Immunol. 1998; 117 (2): 126-130.

  20. Ruffatti A, Rossi L, Calligaro A, Del Ross T, Lagni M, Marson P et al. Autoantibodies of systemic rheumatic diseases in the healthy elderly. Gerontology. 1990; 36 (2): 104-111.

  21. Xavier RM, Yamauchi Y, Nakamura M, Tanigawa Y, Ishikura H, Tsunematsu T et al. Antinuclear antibodies in healthy aging people: a prospective study. Mech Ageing Dev. 1995; 78 (2): 145-154.

  22. Hurme M, Korkki S, Lehtimäki T, Karhunen PJ, Jylhä M, Hervonen A et al. Autoimmunity and longevity: presence of antinuclear antibodies is not associated with the rate of inflammation or mortality in nonagenarians. Mech Ageing Dev. 2007; 128 (5-6): 407-408.

  23. Craig WY, Ledue TB, Johnson AM, Ritchie RF. The distribution of antinuclear antibody titers in “normal” children and adults. J Rheumatol. 1999; 26 (4): 914-319.

  24. Guo YP, Wang CG, Liu X, Huang YQ, Guo DL, Jing XZ et al. The prevalence of antinuclear antibodies in the general population of china: a cross-sectional study. Curr Ther Res Clin Exp. 2014; 76: 116-119.

  25. Minz RW, Kumar Y, Anand S, Singh S, Bamberi P, Verma S et al. Antinuclear antibody positive autoimmune disorders in North India: an appraisal. Rheumatol Int. 2012; 32 (9): 2883-2888.

  26. Ari E, Yildirim M, Kucuk HF, Durmaz F, Dogu Z, Yavuz A et al. Analysis of the humoral immune response to human leukocyte antigens in Turkish renal transplant candidates and relationship between autoimmune disorders. Transplant Proc. 2015; 47 (5): 1326-1330.

  27. Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther. 2009; 11 (5): 252.

  28. Ramos-Casals M, García-Carrasco M, Brito MP, López-Soto A, Font J. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus. 2003; 12 (5): 341-355.

  29. Selmi C, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G et al. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev. 2016; 15 (2): 162-166.

  30. Candore G, Di Lorenzo G, Mansueto P, Melluso M, Fradà G, Li Vecchi M et al. Prevalence of organ-specific and non organ-specific autoantibodies in healthy centenarians. Mech Ageing Dev. 1997; 94 (1-3): 183-190.

  31. Nilsson BO, Skogh T, Ernerudh J, Johansson B, Löfgren S, Wikby A et al. Antinuclear antibodies in the oldest-old women and men. J Autoimmun. 2006; 27 (4): 281-288.

  32. White GL Jr, Wood SD, Rom WN. Prevalence of antinuclear antibodies in a normal male population. Mil Med. 1983; 148 (6): 536-538.

  33. Fritzler MJ. The antinuclear antibody test: last or lasting gasp? Arthritis Rheum. 2011; 63 (1): 19-22.

  34. Brito Fde A, Santos SM, Ferreira GA, Pedrosa W, Gradisse J, Costa LC et al. Detection of anti-nuclear antibodies by indirect immunofluorescence on HEp-2 cells: setting the appropriate screening dilution for the diagnosis of autoimmune rheumatic diseases. Rev Bras Reumatol. 2014; 54 (1): 13-20.

  35. Trevisan S, Nunes J, Schimit S, Fleck J, Souza dos Santos R. Likelihood ratio used to interpretation of autoantibody screening test (FAN-HEp-2) in systemic lupus eritematosus. J Bras Patol Med Lab. 2016; 45 (4): 275-283.

  36. Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol. 2005; 32 (11): 2144-2149.

  37. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012; 39 (11): 2104-2110.

  38. Shinohara T, Singh DP, Chylack LT Jr. Review: Age-related cataract: immunity and lens epithelium-derived growth factor (LEDGF). J Ocul Pharmacol Ther. 2000; 16 (2): 181-191.

  39. Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis Rheum. 2004; 50 (3): 684-688.

  40. Pazini AM, Fleck J, Santos RS, Beck ST. Clinical relevance and frequency of cytoplasmic and nuclear dense fine speckled patterns observed in ANA-HEp-2. Rev Bras Reumatol. 2010; 50 (6): 655-660.




2020     |     www.medigraphic.com